Vivo Bio Tech (Small Cap) Share Target 2024, 2025 To 2039
|
Vivo Bio Tech Limited |
|||
|
Price: ₹37.70 | ||
| 52 Week Low: ₹31.20 52 Week High: ₹56.00 |
|||
| Market Capital: 54.19 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Vivo Bio Tech Share Price Target For 2024
- 1.1.1: Vivo Bio Tech Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Vivo Bio Tech Share Price Target For 2025
- 1.2.1: Vivo Bio Tech Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Vivo Bio Tech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Vivo Bio Tech Financial Performance
- 3.0.1: Is Vivo Bio Tech A Good Buy For Long Term?
To predict the Vivo Bio Tech's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Vivo Bio Tech Share Price Target For 2024
The line chart displays the monthly closing prices of Vivo Bio Tech with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Vivo Bio Tech shares in 2024, see the table below.
Vivo Bio Tech Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 39.78 (+5.51%) | Price Action: 18 Jun 2024 Low |
| 2024 Target 2 | 39.38 (+4.45%) | Price Action: 02 Sep 2024 High |
| 2024 Target 1 | 38.95 (+3.31%) | Price Action: 02 Aug 2024 High |
| Current Price | 37.70 | Vivo Bio Tech's share price as of 26 Dec 2024 |
| Stop Loss 1 | 37.11 (-1.57%) | Price Action: 03 Sep 2024 Low |
| Stop Loss 2 | 36.67 (-2.74%) | Price Action: 16 Aug 2024 Low |
| Stop Loss 3 | 36.3 (-3.72%) | Price Action: 09 Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Vivo Bio Tech is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹37.96 serves as the nearest technical reference point.
Historical Returns: 3-month: -2.56% | 6-month: -6.41% | 1-year: +13.9%
Vivo Bio Tech Share Price Target For 2025
The line chart displays the monthly closing prices of Vivo Bio Tech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Vivo Bio Tech shares in 2025, see the table below.
Vivo Bio Tech Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 55.12 (+46.2%) | Price Action: Chart |
| 2025 Target 2 | 54.09 (+43.47%) | Fibonacci Extension Level 64.90% |
| 2025 Target 1 | 52.9 (+40.31%) | Price Action: 04 Jan 2024 High |
| Current Price | 37.70 | Vivo Bio Tech's share price as of 26 Dec 2024 |
| Stop Loss 1 | 33.94 (-9.98%) | Price Action: 10 Nov 2023 High |
| Stop Loss 2 | 33.6 (-10.88%) | Price Action: 19 Dec 2023 High |
| Stop Loss 3 | 33.26 (-11.78%) | Price Action: 12 Dec 2023 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Vivo Bio Tech is currently trading at 26.2% of its 52-week range (₹31.2 - ₹56).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +13.9% | 3-year: -45.2% | 5-year: +31.36%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Vivo Bio Tech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹37.70 | ||
| 2024 | ₹38.76 | +2.81% | ₹39.34 |
| 2025 | ₹39.18 | +1.08% | ₹41.91 |
| 2026 | ₹39.22 | +0.1% | ₹42.72 |
| 2027 | ₹39.67 | +1.14% | ₹43.54 |
| 2028 | ₹44.36 | +11.82% | ₹45.03 |
| 2029 | ₹41.80 | -5.77% | ₹42.87 |
| 2030 | ₹42.20 | +0.95% | ₹45.17 |
| 2031 | ₹42.20 | 0.00% | ₹45.99 |
| 2032 | ₹42.63 | +1.01% | ₹46.80 |
| 2033 | ₹47.62 | +11.7% | ₹48.33 |
| 2034 | ₹44.83 | -5.85% | ₹46.02 |
| 2035 | ₹45.21 | +0.84% | ₹48.44 |
| 2036 | ₹45.17 | -0.08% | ₹49.25 |
| 2037 | ₹45.59 | +0.92% | ₹50.07 |
| 2038 | ₹50.89 | +11.62% | ₹51.65 |
| 2039 | ₹47.23 | -7.19% | ₹49.17 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Vivo Bio Tech Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 54.19 Crore | Market valuation of Vivo Bio Tech's shares. |
| Revenue (TTM) | 52.23 Crore | Total revenue generated by Vivo Bio Tech over the past twelve months. |
| Net Income (TTM) | +2.64 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +23.49% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +87.03% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+38.72% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
1.15 | Company's total debt divided by total shareholder equity. |
| Total Debt | 60.21 Crore | Sum of Vivo Bio Tech's current & long-term financial obligations. |
Is Vivo Bio Tech A Good Buy For Long Term?
Vivo Bio Tech's recent quarterly report indicates a positive revenue growth of 38.72% compared to the previous quarter, with a high profit margin of 87.03%. Its revenue generation and net profit are positive signs. However, the company's high debt of 60.21 Crore may be a concern. The past 12 months' returns of 71.35% and past 5 years' returns of -42.40% indicate market volatility. Given the company's debt and inconsistent returns, it might be considered an average buy for long-term investors seeking moderate growth.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
